Navigation Links
China Pharma Holdings, Inc. Announces Second Quarter 2008 Financial Results
Date:8/6/2008

NEW YORK and HAIKOU CITY, China, Aug. 6 /Xinhua-PRNewswire-FirstCall/ -- China Pharma Holdings, Inc. ("China Pharma") (OTC Bulletin Board: CPHI) which develops, manufactures, and markets generic and branded bio-pharmaceutical products in China, today announced its financial results for the second quarter of 2008.

Second Quarter 2008 Highlights

-- Second quarter revenues increased 31.6% to $11.28 million

-- Net income increases 21.32% to $4.04 million

-- Sales of bio-product Cerebroprotein increased 125.26% year-over-year.

-- EPS was $0.10, up 15.92% year-over-year

First Half Year 2008 Highlights

-- Revenue increased 45.51% for the same period in 2007 to $23 million

-- Net income was $8.23 million, up 44.34% for the same period in 2007

-- EPS was $0.22, up 39.25% for the same period in 2007

-- Company completed capital raise of $10 million

-- Company launched Bumetanide injection in June 2008

Second Quarter of 2008 Results (Unaudited):

Revenues for the second quarter of 2008 increased 31.6% to $11.3 million compared to $8.6 million for the same quarter in 2007. The growth in revenues was primarily due to organic growth of the existing product portfolio and increasing overall enhanced marketing efforts.

Quarterly gross profit for the second quarter of 2008 was $6 million, compared to $3.9 million for the same period last year, with gross margins of 52.8% and 45.5% respectively. The increase of gross margins was favorably impacted by the increase of revenues of our high margin products. The increase in gross margin reflected the management's clear vision of product selection and development.

Total operating expenses for the three months ended June 30, 2008 were $1.6 million compared to $0.53 million for the same period last year, mainly due to increased revenue and operating expenses. Selling expenses for the period increased to approximately $0.46 million from
'/>"/>

SOURCE China Pharma Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. China Biologic Products Begins Annual Maintenance of its Production Facilities
2. China Pharma Holdings, Inc. to Host Second Quarter 2008 Earnings Conference Call at 10 a.m. EDT Wednesday August 6, 2008
3. China Biologic Products Establishes Audit Committee and Appoints Three New Independent Directors to Board of Directors
4. Global Stem Cell Forum in China Showcases Cutting Edge Research, Focuses on New Findings for iPS Cells
5. China Medical Technologies Adjusts Conversion Rate of Convertible Notes
6. China-Biotics, Inc. Files Application for Nasdaq Listing
7. China Biologic Products Honored with the Advanced Technology Certification for Foreign-Funded Enterprises
8. China-Biotics, Inc. Announces Appointment of New Transfer Agent Effective August 15, 2008
9. China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2008 Financial Results
10. WuXi PharmaTech (NYSE: WX) Named the Most Innovative Company in China and CEO Dr. Li the Most Innovative Leader of Chinese Enterprises
11. China Biologic Products Begins Operation of its Newly Constructed Plasma Collection Station in Qi He County, Shandong Province
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , September 19, 2014 BioTech ... developments, patents and results of studies and trials.  Companies ... and Company (NYSE: LLY ), Gilead Sciences ... CELG ) and Arena Pharmaceuticals Inc. (NASDAQ: ... in developing prodrug therapeutics for the treatment of cancer, ...
(Date:9/19/2014)... The new , Healthcare and Life Sciences Review , ... PharmaBoardroom.com for free download , looks beyond the ... in 2009, and the austerity measures that followed, to find ... of trouble. "Despite the crisis, Spain ... the general conditions to invest are favorable to the pharmaceutical ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 A novel ... an MRI scanner is currently being tested as part ... Women's Hospital in Boston with the aim of determining ... can make prostate cancer biopsies faster, more accurate, less ... system also has the potential to deliver prostate cancer ...
(Date:9/18/2014)... Sept. 18, 2014 Research and Markets ... and Chinese Stem Cell Industry Report, 2014-2017" report ... undifferentiated biological cells that can differentiate into specialized cells ... cells. Stem cell therapy can be applied to treatment ... disease), nervous system diseases, damage or lesion of liver, ...
Breaking Biology Technology:Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 2Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 3Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 4Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 5Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 6Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 7PharmaBoardroom Releases New Spain Pharmaceuticals Report 2PharmaBoardroom Releases New Spain Pharmaceuticals Report 3Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 2Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 3Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 4Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 5Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 6Global and Chinese Stem Cell Industry Report, 2014-2017 2Global and Chinese Stem Cell Industry Report, 2014-2017 3
... First Clinical Milestone Validates Approach, SAN FRANCISCO, ... completion of its first clinical trial, a,proof-of-concept study ... sodium channel blocker. Rufinamide was discovered and,developed by ... Europe as a,drug to treat a form of ...
... January 22 Progentix,Orthobiology B.V. announced today the ... was led by BioGeneration Ventures., Progentix Orthobiology ... suite of osteoinductive material products for clinical application,in ... based on,surface structured ceramic biomaterial scaffolds that have ...
... year the NorTech Venture,Capital Advisory Task Force reported in ... need to generate and attract over $1.2 billion,in venture ... needs of companies,located in Northeast Ohio. According to the ... the Cleveland+ region, to be,released in print mid February, ...
Cached Biology Technology:Synosia Announces Encouraging Results of Proof-of-Concept Clinical Trial for Epilepsy Drug rufinamide as a Treatment for Mood Disorders 2Synosia Announces Encouraging Results of Proof-of-Concept Clinical Trial for Epilepsy Drug rufinamide as a Treatment for Mood Disorders 3Progentix Orthobiology B.V. Closes Series A Financing Round 2Cleveland+ Region Attracts $318 Million in New Venture Investment in 2007 2Cleveland+ Region Attracts $318 Million in New Venture Investment in 2007 3Cleveland+ Region Attracts $318 Million in New Venture Investment in 2007 4Cleveland+ Region Attracts $318 Million in New Venture Investment in 2007 5
(Date:9/18/2014)... The ability to acquire and creatively manipulate spoken language ... over the past 6 million years of human evolution ... is the best candidate gene we now have," says ... LMU. In his efforts to understand the molecular biological ... step forward. The results of his latest study, undertaken ...
(Date:9/18/2014)... across racial and ethnic groups describe losing eyesight ... day-to-day life, more so than other conditions including: ... of African-Americans, 49% of non-Hispanic whites, 43% of ... disease or ailment is the worst that could ... followed by AIDS/HIV. Hispanics and Asians ranked ...
(Date:9/18/2014)... and nitrogen comprise all spheres of our planet. ... caused imbalances and perturbations that resulted in increases ... result in climate changes which influence the complex ... atmosphere. Understanding these feedback mechanisms has become an ... during the past three decades. , In parallel, ...
Breaking Biology News(10 mins):Language evolution: Quicker on the uptake 2Language evolution: Quicker on the uptake 3Americans rate losing eyesight as having greatest impact on their lives 2Americans rate losing eyesight as having greatest impact on their lives 3Greenhouse gas research enters a new era 2
... at the University of California, San Francisco (UCSF) has ... to a common but untreatable and incurable neurodegenerative disease. ... common cause of dementia before age 65, after Alzheimer,s ... the UCSF team,s work explains in part why the ...
... available in French . The Universit ... of the Botanical Garden. The new Centre, the result of ... the Montral Insectarium, two Espace pour la vie (Montral Space ... biodiversity, its preservation and its promotion. The Centre will not ...
... LA LSU oncologist Vince D. Cataldo, MD, is ... chemotherapy drugs now indicated for second and third-line therapy ... effective in treating a certain subset of these patients. ... LSU Health Sciences Center New Orleans School of Medicine, ...
Cached Biology News:UCSF report describes new model for neurodegeneration 2UCSF report describes new model for neurodegeneration 3The University of Montreal Biodiversity Centre opens 2The University of Montreal Biodiversity Centre opens 3Study shows new treatment strategy effective for certain lung cancers 2
Mouse polyclonal antibody raised against a partial recombinant DDEF2. NCBI Entrez Gene ID = 8853...
Mouse monoclonal antibody raised against a full length recombinant SCGB3A2. NCBI Entrez Gene ID = SCGB3A2...
Mouse monoclonal antibody raised against a partial recombinant QARS. NCBI Entrez Gene ID = QARS...
Mouse polyclonal antibody raised against a partial recombinant QPCT. NCBI Entrez Gene ID = 25797...
Biology Products: